News
-
Padagis has announced a $36 million expansion of its manufacturing facilities in Minneapolis, MN, USA, specifically highlighting the new capacity to manufacture naloxone nasal spray in the US. According to the company, “The additional capabilities… Read more . . .
-
The 2025 edition of the Drug Delivery to the Lungs (DDL) meeting is once again expected to draw approximately 1,100 inhaled and nasal drug delivery experts to the Edinburgh International Conference Centre (EICC). The conference,… Read more . . .
-
According to Amneal Pharmaceuticals, the FDA has tentatively approved Amneal’s ANDA for a generic of Teva’s QVAR beclomethasone dipropionate HFA MDI, 40 μg/actuation and 80 μg/actuation, for the treatment of asthma. The company notes that… Read more . . .
-
ENA Respiratory has announced the closing of a $22.4 million Series B financing, including a previously announced $5 million investment from the Flu Lab and participation by the Gates Foundation. The proceeds will be used… Read more . . .
-
Tonix Pharmaceuticals announced that Massachusetts General Hospital has initiated a Phase 1 trial called FOCUS to evaluate Tonix’s TNX-1900 and TNX-2900 oxytocin nasal sprays in patients with arginine-vasopressin deficiency (central diabetes insipidus). The FOCUS study… Read more . . .
-
GSK has announced that a Phase 3 trial comparing an HFA-152a formulation of Ventolin salbutamol (albuterol) MDI to the currently marketed HFA-134a formulation demonstrated therapeutic equivalence. The company also said that safety of the LGWP propellant… Read more . . .
-
OINDP specialist CDMO Kenox Pharmaceuticals has announced the appointment of Julianne Berry as VP of R&D and Manufacturing. Berry was most recently VP, Respiratory Product Development at Odin Pharmaceuticals and has extensive experience in the development of inhaled… Read more . . .
-
Italian biotech Dompé announced that the US FDA has awarded a voucher under the new Commissioner’s National Priority Voucher (CNPV) pilot program for accelerated review of an application for the company’s intranasal cenegermin-bkbj (recombinant human… Read more . . .
-
Orbia has announced the delivery of 17 tonnes of Koura Global’s Zephex 152a (HFA-152a), an LGWP propellant, to Kindeva Drug Delivery‘s facility in Loughborough, UK where the CDMO has MDI manufacturing lines for LGWP propellants. Kindeva… Read more . . .
-
According to Beckley Psytech and atai Life Sciences, the FDA has granted Breakthrough Therapy designation to Beckley’s BPL-003 intranasal mebufotenin (5-MeO-DMT) for the treatment of treatment-resistant depression. Earlier this year, the companies announced that a Phase… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA